Ionis Pharmaceuticals, Inc. Total Liabilities
Ionis Pharmaceuticals, Inc. (IONS) had Total Liabilities of $2.55 billion as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Balance Sheet › Liabilities
us-gaap:Liabilities · last filed 2026-07-29
- 2026-06-30: Liabilities $2.55B.
- 2026-03-31: Liabilities $2.96B.
- 2025-12-31: Liabilities $3.03B.
- 2025-09-30: Liabilities $2.42B.
| Period end | Liabilities | Liabilities as first filed |
|---|---|---|
| 2026-06-30 | $2.55B 10-Q · filed 2026-07-29 | |
| 2026-03-31 | $2.96B 10-Q · filed 2026-04-29 | |
| 2025-12-31 | $3.03B 10-Q · filed 2026-07-29 | |
| 2025-09-30 | $2.42B 10-Q · filed 2025-10-29 | |
| 2025-06-30 | $2.35B 10-Q · filed 2025-07-30 | |
| 2025-03-31 | $2.34B 10-Q · filed 2025-04-30 | |
| 2024-12-31 | $2.42B 10-K · filed 2026-02-26 | |
| 2024-09-30 | $2.42B 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $2.43B 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $2.47B 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $2.60B 10-K · filed 2025-02-19 | |
| 2023-09-30 | $2.62B 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $2.54B 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $2.40B 10-Q · filed 2023-05-03 | |
| 2022-12-31 | $1.96B 10-K · filed 2024-02-21 | |
| 2022-09-30 | $1.83B 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $1.83B 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $1.81B 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $1.84B 10-K · filed 2023-02-22 | |
| 2021-09-30 | $1.88B 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $1.91B 10-Q · filed 2021-08-04 | |
| 2021-03-31 | $1.57B 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $1.65B 10-K · filed 2022-02-25 | $1.55B 10-K · filed 2021-02-24 |
| 2020-09-30 | $1.49B 10-Q · filed 2020-11-04 | |
| 2020-06-30 | $1.48B 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $1.52B 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $1.55B 10-K · filed 2021-02-24 | |
| 2019-09-30 | $1.40B 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $1.42B 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $1.45B 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $1.48B 10-K · filed 2020-03-02 | |
| 2018-09-30 | $1.41B 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $1.43B 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $912.46M 10-Q · filed 2018-05-07 | |
| 2017-12-31 | $957.49M 10-K · filed 2019-03-01 | $903.30M 10-K · filed 2018-02-28 |
| 2017-09-30 | $854.89M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $875.26M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $882.19M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $812.90M 10-K · filed 2018-02-28 | |
| 2016-09-30 | $703.95M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $699.90M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $717.66M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $747.11M 10-K · filed 2017-03-01 | $755.32M 10-K · filed 2016-02-26 |
| 2015-09-30 | $742.59M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $675.94M 10-Q · filed 2015-08-05 | |
| 2015-03-31 | $679.58M 10-Q · filed 2015-05-05 | |
| 2014-12-31 | $698.03M 10-K · filed 2016-02-26 | |
| 2014-09-30 | $449.03M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $450.92M 10-Q · filed 2014-08-04 | |
| 2014-03-31 | $460.51M 10-Q · filed 2014-05-06 | |
| 2013-12-31 | $468.77M 10-K · filed 2015-03-02 | |
| 2013-09-30 | $480.47M 10-Q · filed 2013-11-05 | |
| 2013-06-30 | $387.57M 10-Q · filed 2013-08-06 | |
| 2013-03-31 | $351.87M 10-Q · filed 2013-05-07 | |
| 2012-12-31 | $362.92M 10-K · filed 2014-03-03 | |
| 2012-09-30 | $315.40M 10-Q · filed 2012-11-06 | |
| 2012-06-30 | $318.08M 10-Q · filed 2012-08-06 | |
| 2012-03-31 | $319.94M 10-Q · filed 2012-05-09 | |
| 2011-12-31 | $313.46M 10-K · filed 2013-02-28 | |
| 2011-09-30 | $318.96M 10-Q · filed 2011-11-08 | |
| 2011-06-30 | $317.36M 10-Q · filed 2011-08-08 | |
| 2011-03-31 | $278.24M 10-Q · filed 2011-05-06 | |
| 2010-12-31 | $305.94M 10-K · filed 2012-02-29 | |
| 2010-09-30 | $322.15M 10-Q · filed 2010-11-05 | |
| 2010-06-30 | $344.12M 10-Q · filed 2010-08-09 | |
| 2009-12-31 | $355.12M 10-K · filed 2011-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |